Mar 26 |
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
|
Mar 25 |
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
|
Mar 21 |
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript
|
Mar 21 |
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
|
Mar 20 |
Valneva SE (VALN) Q4 2023 Earnings Call Transcript
|
Mar 20 |
Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance
|
Mar 20 |
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
|
Mar 18 |
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
|
Mar 6 |
VALNEVA Declaration of shares and voting rights - February 29, 2024
|
Mar 4 |
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
|